Save time and get answers to complex questions with AI chat
When will latisse patent expire?Symbravo ingredients mechanism of action?Abbvie humira patent cliff navigation success?Does lipitor's effectiveness decrease with high fat meals?Guselkumab loss of exclusitivy?
See the DrugPatentWatch profile for Leuprolide
I don’t have real-time market-share numbers here. Market share for leuprolide acetate products varies by region, year, and whether you’re looking at brand-only vs. including generics or by prescriptions vs. sales. If you can share: - region (US, global, or another country) - year or range (e.g., 2023–2024) - whether you want brand-only or including generics - whether you want prescriptions, units, or sales value I can provide a more precise answer or pull the latest published figures from sources like IQVIA Drug Channels Institute, company annual reports, or market analyses. If you’d like, I can also outline the main leuprolide formulations and brands you’ll typically see: - Lupron (brand by AbbVie/Takeda lineage) – commonly the leading brand in many markets - Eligard (long-acting subcutaneous formulation) – a major competitor in the US - Viadur (leuprolide implant) – smaller share in many markets - Generics/injectables – compete on price where available Tell me what you prefer, and I’ll tailor the data.
Other Questions About Leuprolide :